FDMT vs. CMRX, CRON, QURE, OCS, ANAB, BGM, CRMD, VIR, KALV, and AMLX
Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Chimerix (CMRX), Cronos Group (CRON), uniQure (QURE), Oculis (OCS), AnaptysBio (ANAB), BGM Group (BGM), CorMedix (CRMD), Vir Biotechnology (VIR), KalVista Pharmaceuticals (KALV), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry.
4D Molecular Therapeutics vs. Its Competitors
4D Molecular Therapeutics (NASDAQ:FDMT) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.
In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Chimerix. MarketBeat recorded 3 mentions for 4D Molecular Therapeutics and 0 mentions for Chimerix. 4D Molecular Therapeutics' average media sentiment score of 0.49 beat Chimerix's score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.
Chimerix has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. 4D Molecular Therapeutics' return on equity of -33.26% beat Chimerix's return on equity.
Chimerix has higher revenue and earnings than 4D Molecular Therapeutics. Chimerix is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
4D Molecular Therapeutics has a beta of 2.81, indicating that its share price is 181% more volatile than the S&P 500. Comparatively, Chimerix has a beta of -0.17, indicating that its share price is 117% less volatile than the S&P 500.
4D Molecular Therapeutics currently has a consensus price target of $29.56, indicating a potential upside of 600.37%. Chimerix has a consensus price target of $8.53, indicating a potential downside of 0.08%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Chimerix.
99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 9.6% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Chimerix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
4D Molecular Therapeutics beats Chimerix on 11 of the 16 factors compared between the two stocks.
Get 4D Molecular Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
4D Molecular Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FDMT) was last updated on 7/18/2025 by MarketBeat.com Staff
